title: [Intravitreal Triamcinolone Acetonide for Persistent Diabetic Macular Edema after Vitrectomy].
abstract: OBJECTIVE
  To determine whether intravitreal triamcinolone acetonide (IVTA) is effective in resolving edema in eyes with persistent diabetic macular edema (DME) after vitrectomy.
  
  
  METHODS
  Sixteen eyes of 16 patients were given 4 mg IVTA after vitrectomy for DME. The best-corrected visual acuity (BCVA), central macular thickness (CMT), and average threshold (AT) of the central retina were determined during the 24 weeks follow-up period. Patients were divided into two groups; early treatment group and late treatment group.
  
  
  RESULTS
  The BCVA was significantly improved at 12 weeks, the CMT was significantly improved at 24 weeks, and the AT was significantly improved at 4 weeks after IVTA (repeated ANOVA, p < 0.05). The BCVA was more significantly improved in the early treatment group than in the late treatment group at 4 and 12 weeks (unpaired t test, p < 0.05).
  
  
  CONCLUSIONS
  Our results indicate that IVTA should be considered as treatment for patients with persistent DME after vitrectomy, especially with early treatment patients.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Ichio
authors.forename: Masahiko
authors.initials: M
authors.lastname: Sugimoto
authors.forename: Mineo
authors.initials: M
authors.lastname: Kondo
mesh_terms: D000368:Aged; D048909:Diabetes Complications / Q000188:drug therapy*; D003920:Diabetes Mellitus; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D014222:Triamcinolone Acetonide / Q000008:administration & dosage / Q000627:therapeutic use*; D014821:Vitrectomy / Q000009:adverse effects*
chemical_list: D014222:Triamcinolone Acetonide